Long‐term efficacy and safety of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: The results of a phase 2 study (B‐1201)-Reference-Cited by-同舟云学术

Long‐term efficacy and safety of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: The results of a phase 2 study (B‐1201)

Published:2019-05-15 Issue:7 Volume:46 Page:557-563
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Hamada Toshihisa¹²^ORCID,Tokura Yoshiki³,Sugaya Makoto⁴,Ohtsuka Mikio⁵^ORCID,Tsuboi Ryoji⁶,Nagatani Tetsuo⁷,Kiyohara Eiji⁸,Tani Mamori⁸,Setoyama Mitsuru⁹,Matsushita Shigeto¹⁰¹¹,Kawai Kazuhiro¹⁰^ORCID,Yonekura Kentaro¹²,Saida Toshiaki¹³^ORCID,Iwatsuki Keiji¹^ORCID

Affiliation:

1. Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

2. Department of Dermatology Takamatsu Red Cross Hospital Takamatsu Japan

3. Department of Dermatology Hamamatsu University School of Medicine Shizuoka Japan

4. Department of Dermatology International University of Health and Welfare Chiba Japan

5. Department of Dermatology Fukushima Medical University Fukushima Japan

6. Department of Dermatology Tokyo Medical University Tokyo Japan

7. Department of Dermatology Tokyo Medical University Hachioji Medical Center Tokyo Japan

8. Department of Dermatology Graduate School of Medicine Osaka University Osaka Japan

9. Department of Dermatology Faculty of Medicine University of Miyazaki Miyazaki Japan

10. Department of Dermatology Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan

11. Department of Dermato‐Oncology/Dermatology National Hospital Organization Kagoshima Medical Center Kagoshima Japan

12. Department of Dermatology Imamura General Hospital Kagoshima Japan

13. Department of Dermatology Shinshu University Nagano Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.14923

Reference21 articles.

1. WHO-EORTC classification for cutaneous lymphomas

2. Cutaneous lymphoma in Japan: A nationwide study of 1733 patients

3. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

4. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

5. Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023;European Journal of Cancer;2023-12

2. Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene;Case Reports in Oncology;2022-02-01

3. Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma;Dermatology and Therapy;2022-01-27

4. Current treatment strategies and emerging therapies for cutaneous lymphoma;The Journal of Dermatology;2021-12-27

5. Efficacy and Safety of Oral Bexarotene for Japanese Patients with Mycosis Fungoides : A Retrospective Case-Series Study of a Single Medical Center in Japan;Nishi Nihon Hifuka;2021-12-01